Gilead Sciences Live Stock Price Today, Share Analysis and Chart

Name: Gilead Sciences, Inc.: Is Infosys Ltd. worth buying?
Item: Gilead Sciences, Inc.
Rating: 1.624861125
Author: Trendlyne DVM scores

Momentum Trap

about

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Soval...

151.37 1.26 (0.84%)

Near 52W High of $157.29

1.9M

XNAS Volume

XNAS 21 Sep, 2026 12:13 PM (EDT)

Low Financial Strength

27.8 / 100

Expensive Valuation

18.8 / 100

Technically Neutral

55.6 / 100

Momentum Trap These stocks have weak financials and expensive valuation. Medium technical scores may weaken. Investors should exercise caution View Similar Embed DVM

158

1Yr Price target upside is 4%

27 analysts

Gilead Sciences Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Gilead Sciences Live Stock Price Today, Share Analysis and Chart

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Soval...

Near 52W High of $157.29

SWOT Analysis

Gilead Sciences Live Price Chart

Gilead Sciences Live Price Chart